During a press conference Tuesday at the International AIDS Conference in Vienna, Anthony Fauci, MD, Director of the National Institute of Allergy and Infectious Diseases at NIH, describes the Vaginal and Oral Interventions to Control the Epidemic (VOICE) trial. The study is testing the safety and efficacy of microbicide gel containing the ARV drug tenofovir, and oral tablets containing tenofovir or a combination of tenofovir and emtricitabine known by the brand name Truvada.
Integrating services works to curb HIV transmission from mothers to their infants and retain mothers in care, study shows
The following is a guest post by Emily Bobrow, PhD, of MEASURE Evaluation A combination of integrated service delivery approaches for mothers who are living with […]
Suppose you have a large group of people, confined together, considered likely to pose a threat to people outside their walls, but without the ready means […]
This year marks the close of a dynamic decade in global infectious disease research and responses that changed expectations of what humanity can accomplish toward making […]
2019 nCoV: With quarantines, novel coronavirus brings new and existing public health preparedness needs to the forefront
The following is a guest post by Jeffrey Duchin, MD, FIDSA The quarantine and travel restrictions announced by the US federal government in response to the […]